Heidelberg Pharma AG has expanded its management team with the appointment of Mathias Locher to the newly created position of chief development officer. Simultaneously, it has promoted András Strassz to the position of chief medical officer. Heidelberg Pharma is developing antibody conjugate technology for cancer.
Dr Locher joins the company from Janssen Pharmaceutical Companies where he directed external innovation at a hub in London, UK. He holds a PhD in biochemistry from the University of Tübingen in Germany.
Dr Strassz has been senior medical officer since April 2020 having joined Heidelberg from Affimed NV. He holds both a medical degree and a master’s in business administration from the University of Pécs in Hungary.
Heidelberg Pharma announced the appointment on 1 March 2021.
Copyright 2021 Evernow Publishing Ltd